RxDoctor Payments Data

Mahmoud Abdou, MD

Advanced Heart Failure and Transplant Cardiology · Atlanta, GANPI 1518283282

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,874 of the $4,351 with a category attached, or 66.1%. Abbott accounts for 77.4% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $1,951, 2.0 times the $955 reported in 2019. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in GA, where the typical reported total is $8,076.

$4,351in general payments, 2019–2025

Across 84 payments — averaging $51.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Novartis$356
  • Amgen$132
  • Pfizer$123
  • Alnylam Pharmaceuticals Inc.$121
  • Daiichi Sankyo Inc.$62
  • plus $190 from 7 others

What the payments were for

  • Travel & lodging$2,87466%
  • Food & beverage$1,47734%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,351 in reported general payments places this provider in the 40th percentile of 40 advanced heart failure and transplant cardiology providers in Georgia.

See all advanced heart failure and transplant cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$61,538
Medicare patients
207
Services billed
597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan196$242,669
JardianceEmpagliflozin170$167,220
FarxigaDapagliflozin Propanediol150$141,880
EliquisApixaban113$121,900
XareltoRivaroxaban20$17,430
Tacrolimus55$13,254
BrilintaTicagrelor12$10,997
Atovaquone13$5,061
Torsemide247$4,417
Sirolimus16$3,679
Spironolactone361$2,973
Mycophenolate Mofetil30$2,395
Metoprolol Succinate208$2,307
Eplerenone24$1,856
Potassium Chloride67$1,359

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$356$242,669196 claims
AstraZenecaFarxiga, Brilinta$14$152,877162 claims
PfizerEliquis$123$121,900113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 40 advanced heart failure and transplant cardiology providers in Georgia.

Other advanced heart failure and transplant cardiology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →